PRO-TECT is a randomized trial that innovatively integrated financial toxicity screening into a pre-existing digital symptom-monitoring programme, enabling longitudinal detection of financial toxicity. Such a strategy provides an unobtrusive and cost-effective method for early detection and mitigation of financial toxicity by aligning the needs of patients and carers with the resources available in community clinical practices.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shankaran, V. et al. Risk of adverse financial events in patients with cancer: evidence from a novel linkage between cancer registry and credit records. J. Clin. Oncol. 40, 884–891 (2022).
Ramsey, S. et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff. 32, 1143–1152 (2013).
Ramsey, S. D. et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J. Clin. Oncol. 34, 980–986 (2016).
Lathan, C. S. et al. Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J. Clin. Oncol. 34, 1732–1740 (2016).
Blinder, V. S. et al. Financial toxicity monitoring in a randomized controlled trial of patient-reported outcomes during cancer treatment (Alliance AFT-39). J. Clin. Oncol. 41, 4652–4663 (2023).
de Souza, J. A. et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the comprehensive score for financial toxicity (COST). Cancer 123, 476–484 (2017).
Shankaran, V. et al. S1417CD: a prospective multicenter cooperative group-led study of financial hardship in metastatic colorectal cancer patients. J. Natl. Cancer Inst. 114, 372–380 (2022).
Sidey-Gibbons, C. et al. Development of machine learning algorithms for the prediction of financial toxicity in localized breast cancer following surgical treatment. JCO Clin. Cancer Inform. 5, 338–347 (2021).
de Moor, J. S. et al. Delivery of financial navigation services within national cancer institute-designated cancer centers. JNCI Cancer Spectr. 5, pkab033 (2021).
Sadigh, G., Coleman, D., Switchenko, J. M., Hopkins, J. O. & Carlos, R. C. Treatment out-of-pocket cost communication and remote financial navigation in patients with cancer: a feasibility study. Support. Care Cancer 30, 8173–8182 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
FACIT-COST: https://www.facit.org/measures/FACIT-COST
National Comprehensive Cancer Network Distress Thermometer: https://www.nccn.org/docs/default-source/patient-resources/nccn_distress_thermometer.pdf
Rights and permissions
About this article
Cite this article
Su, C.T., Shankaran, V. Digital symptom assessment tools: the next frontier in financial toxicity screening. Nat Rev Clin Oncol 21, 85–86 (2024). https://doi.org/10.1038/s41571-023-00833-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00833-3
